Table 1.
Baseline characteristics of participants
| No PRT |
PRT |
||||||
|---|---|---|---|---|---|---|---|
| Placebo (n = 21) | Lower-range T (n = 19) | Higher-range T (n = 22) | Placebo (n = 19) | Lower-range T (n = 22) | Higher-range T (n = 21) |
P value |
|
| Characteristic | |||||||
| Age, yr | 67 ± 5 | 66 ± 5 | 67 ± 6 | 66 ± 5 | 69 ± 8 | 66 ± 5 | 0.69 |
| Race | 0.63 | ||||||
| White | 21 (100.0) | 19 (100.0) | 20 (90.9) | 18 (94.7) | 20 (90.9) | 20 (95.2) | |
| Black | 0 (0.0) | 0 (0.0) | 1 (4.5) | 1 (5.3) | 2 (9.1) | 1 (4.8) | |
| Other | 0 (0.0) | 0 (0.0) | 1 (4.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Ethnicity | 0.69 | ||||||
| Hispanic | 1 (4.8) | 0 (0.0) | 1 (4.3) | 1 (4.2) | 0 (0.0) | 0 (0.0) | |
| Non-Hispanic | 20 (95.2) | 19 (100.0) | 21 (95.5) | 19 (100.0) | 22 (100.0) | 21 (100.0) | |
| Education, yr | 16 ± 2 | 16 ± 3 | 16 ± 2 | 16 ± 2 | 17 ± 2 | 15 ± 3 | 0.66 |
| Weight, kg | 84.3 ± 11.8 | 92.8 ± 12.1 | 87.6 ± 12.6 | 91.3 ± 13.0 | 89.5 ± 9.5 | 87.6 ± 11.0 | 0.26 |
| BMI, kg/m2 | 27.2 ± 3.0 | 28.9 ± 3.0 | 28.2 ± 3.3 | 28.9 ± 3.4 | 26.8 ± 2.0 | 27.9 ± 2.8 | 0.14 |
| Total body fat, % | 26.9 ± 5.3 | 29.4 ± 4.3 | 28.5 ± 4.8 | 29.1 ± 4.0 | 28.4 ± 4.3 | 30.3 ± 4.2 | 0.27 |
| Systolic BP, mmHg (seated) | 129 ± 19 | 133 ± 18 | 126 ± 13 | 129 ± 16 | 122 ± 11 | 125 ± 19 | 0.43 |
| Diastolic BP, mmHg (seated) | 75 ± 9 | 77 ± 8 | 75 ± 7 | 79 ± 9 | 75 ± 8 | 77 ± 8 | 0.45 |
| V̇o2max, ml·kg−1·min−1 | 26.1 ± 5.1 | 25.4 ± 4.9 | 25.7 ± 5.6 | 25.3 ± 3.4 | 24.1 ± 7.1 | 24.5 ± 4.6 | 0.83 |
| Antihypertensive medication | 13 (61.9) | 10 (52.6) | 11 (50.0) | 11 (57.9) | 10 (45.5) | 11 (52.4) | 0.92 |
| Lipid-lowering medication | 11 (57.9) | 12 (54.5) | 9 (42.9) | 8 (42.1) | 10 (45.5) | 12 (57.1) | 0.88 |
| Aspirin | 12 (57.1) | 8 (42.1) | 14 (63.6) | 11 (57.9) | 8 (36.4) | 13 (61.9) | 0.38 |
| NSAID | 5 (23.8) | 8 (42.1) | 3 (13.6) | 5 (26.3) | 3 (13.6) | 3 (14.3) | 0.19 |
Data are mean ± standard deviation or number (percent). BMI, body mass index; BP, blood pressure; NSAID, nonsteroidal anti-inflammatory drug; PRT, progressive resistance training; T, testosterone; V̇o2max, maximal aerobic power.